Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APADAZ vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Relief of moderate to moderately severe pain
Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Terminal elimination half-life: 2-4 hours for benzhydrocodone; context: immediate-release, dosing every 4-6 hours.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Benzhydrocodone is converted to hydrocodone by intestinal and hepatic enzymes (e.g., esterases). Hydrocodone is metabolized via CYP3A4 and CYP2D6 to norhydrocodone, hydromorphone, and other metabolites. Acetaminophen is primarily metabolized by glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); a minor amount is oxidized by CYP2E1, CYP1A2, and CYP3A4 to the reactive metabolite NAPQI, which is conjugated with glutathione.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Renal: ~90% as conjugates, ~10% unchanged; fecal: minimal; enterohepatic recirculation occurs.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Benzhydrocodone: ~20% bound to albumin; acetaminophen: 10-25% bound.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Benzhydrocodone: ~3-5 L/kg; context: extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Oral: ~50% for benzhydrocodone (due to first-pass metabolism); acetaminophen: 60-90%.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²). For moderate impairment (e GFR 30-59 m L/min/1.73m²), initiate with lowest dose and monitor; do not exceed 6 tablets per day.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh C). For moderate impairment (Child-Pugh B), reduce dose by 50% and monitor; maximum 6 tablets per day. Mild impairment (Child-Pugh A): no adjustment but monitor.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended for pediatric patients under 18 years of age.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate with lowest dose (1 tablet every 6 hours as needed); do not exceed 6 tablets per day; monitor for respiratory depression, falls, and cognitive impairment.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; risks from concomitant use with benzodiazepines or other CNS depressants; neonatal opioid withdrawal syndrome; and risks associated with use of acetaminophen (hepatotoxicity).
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Life-threatening respiratory depression,Addiction, abuse, and misuse,Risks from concomitant use with benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome,Hepatotoxicity from acetaminophen,Severe hypotension,Gastrointestinal adverse reactions (e.g., constipation, ileus),Seizures in patients with seizure disorders,Adrenal insufficiency,Risks in patients with head injury or increased intracranial pressure
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction (e.g., paralytic ileus),Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation,Severe hepatic impairment (acetaminophen component)
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Avoid alcohol. Grapefruit juice may alter metabolism via CYP3A4 inhibition; consider limiting intake. High-fat meals can increase absorption of benzhydrocodone; take consistently with or without food to maintain effect.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Apadaz (benzhydrocodone/acetaminophen) is a combination opioid/acetaminophen product. Opioid use during pregnancy may cause neonatal opioid withdrawal syndrome (NOWS) with prolonged use; risk is highest in third trimester. Acetaminophen is not teratogenic at therapeutic doses. FDA Pregnancy Category C (prior to 2019 labeling); current labeling advises use only if potential benefit justifies potential risk to fetus. First trimester: limited data; opioid use associated with neural tube defects in some studies, but confounding by maternal factors. Second trimester: no specific malformation risk. Third trimester: risk of NOWS, preterm labor, and intrauterine growth restriction with chronic use. Avoid prolonged use; acute use at standard doses is not associated with major teratogenic risk.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Benzhydrocodone is a prodrug of hydrocodone; both hydrocodone and acetaminophen are excreted into breast milk. Hydrocodone M/P ratio is approximately 2.0 (milk:plasma concentration ratio). Acetaminophen M/P ratio is approximately 1.0. Low absolute infant dose; relative infant dose is about 2-4% of maternal weight-adjusted dose for hydrocodone and 10-20% for acetaminophen. AAP considers acetaminophen compatible with breastfeeding. Opioids should be used with caution; monitor infant for sedation, respiratory depression, and poor feeding. Avoid in mothers with CYP2D6 ultra-rapid metabolizer phenotype due to risk of increased morphine conversion.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Pharmacokinetic changes in pregnancy (increased plasma volume, hepatic enzyme induction, altered opioid clearance): For acute pain, use lowest effective dose for shortest duration. Consider dose reduction postpartum as metabolic changes resolve. No specific dose adjustment guidelines for Apadaz; clinical judgment for opioid dose titration needed. Monitor for inadequate analgesia or withdrawal due to increased clearance. For chronic pain, consider tapering or alternative non-opioid therapy.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Contains benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Abuse-deterrent properties due to enzymatic activation required in GI tract; consider in patients with risk of opioid misuse. Monitor for acetaminophen hepatotoxicity; max daily acetaminophen dose from all sources should not exceed 4 g. Avoid in severe hepatic impairment. Onset of analgesia is slower than immediate-release hydrocodone due to prodrug conversion.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take exactly as prescribed; do not crush, chew, or dissolve tablets as this can cause rapid release and overdose.,Avoid alcohol and other CNS depressants; may cause severe drowsiness, respiratory depression, or coma.,Do not take other acetaminophen-containing products; check labels for acetaminophen (APAP) to prevent liver damage.,Store securely and dispose of unused medication via take-back programs; prevent misuse by others.,Common side effects include nausea, constipation, dizziness, and drowsiness; contact prescriber if severe or persistent.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APADAZ vs ANEXSIA, answered by our medical review team.
APADAZ is a Opioid Analgesic that works by APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APADAZ and ANEXSIA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APADAZ is: Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APADAZ and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APADAZ is classified as Category C. Apadaz (benzhydrocodone/acetaminophen) is a combination opioid/acetaminophen product. Opioid use during pregnancy may cause neonatal opioid withdrawal syndrome (NOWS) with prolonge. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.